NCT04205552View on ClinicalTrials.gov

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
NSCLC Stage IINSCLC, Stage IIIANSCLC, Stage I
Interventions
DRUG

Nivolumab 10 MG/ML Intravenous Solution

Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min

DRUG

Relatlimab 10 MG/ML Intravenous Solution

Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min

Trial Locations (4)

69126

RECRUITING

Thoraxklinik Heidelberg gGmbH-Universitätsklinikum Heidelberg, Heidelberg

Unknown

RECRUITING

Jessa Hospital Hasselt, Hasselt

RECRUITING

University Hospital Essen, Essen

RECRUITING

Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
lead

University Hospital, Essen

OTHER